- Home
- HOLO vs LGVN Comparison
HOLO vs LGVN Comparison
Compare HOLO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | LGVN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 17.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HOLO | LGVN |
|---|---|---|
| Price | $2.98 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | ★ 508.2K | 470.2K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 13.81 | N/A |
| Revenue | ★ $44,840,587.00 | $1,437,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.21 | ★ N/A |
| Revenue Growth | ★ 37.10 | N/A |
| 52 Week Low | $2.77 | $0.53 |
| 52 Week High | $370.00 | $2.24 |
Technical Indicators
Market Signals| Indicator | HOLO | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 35.83 |
| Support Level | $2.86 | $0.54 |
| Resistance Level | $3.20 | $0.63 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 11.54 | 8.37 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.